The molecular mechanism underlying the proliferation of colorectal cancer (CRC) cells is not completely understood. Here, we found that the level of neuregulin receptor degradation protein-1 (Nrdp1) E3 ubiquitin ligase was significantly decreased in CRC tissues, compared with the adjacent normal tissues from human patients. Knockdown of Nrdp1 enhanced the proliferation of CRC cells, while overexpression of Nrdp1 inhibited the proliferation of CRC cells. Further analysis showed that Nrdp1 may induce degradation of its target ErbB3 to inhibit activation of both ERK/MAPK and PI3K/Akt pathways in CRC cells, which seemed to affect cell proliferation via nuclear retention of a major cell-cycle inhibitor, p27. Taken together, these findings suggest that Nrdp1-mediated ErbB3 degradation suppresses cellular growth of CRC and that Nrdp1 loss in CRC may promote tumor progression, thus highlighting Nrdp1 as a novel target for CRC therapy.
Neuregulin receptor degradation protein-1 (Nrdp1) ErbB3 Extracellular-related kinase/mitogen-activated protein kinase (ERK/MAPK) Phosphatidylinositol 3-kinase (PI3K) Protein kinase B (Akt) Colorectal cancer
This is a preview of subscription content, log in to check access.
This work was supported by the internal funding of the First Affiliated Hospital, Liaoning Medical College, China.
Conflicts of interest
East JE, Dekker E. Colorectal cancer diagnosis in 2012: a new focus for CRC prevention—more serration, less inflammation. Nat Rev Gastroenterol Hepatol. 2013;10:69–70.CrossRefPubMedGoogle Scholar
Van Schaeybroeck S, Allen WL, Turkington RC, Johnston PG. Implementing prognostic and predictive biomarkers in CRC clinical trials. Nat Rev Clin Oncol. 2011;8:222–32.CrossRefPubMedGoogle Scholar
Labianca R, Beretta GD, Mosconi S, Pessi MA, Milesi L. The development of clinical research in CRC. Ann Oncol. 2005;16 Suppl 4:iv37–43.PubMedGoogle Scholar
Pandurangan AK. Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mtor and Wnt pathways. Asian Pac J Cancer Prev. 2013;14:2201–5.CrossRefPubMedGoogle Scholar
Qi J, Zhu YQ. Targeting the most upstream site of wnt signaling pathway provides a strategic advantage for therapy in colorectal cancer. Curr Drug Targets. 2008;9:548–57.CrossRefPubMedGoogle Scholar
Ye Q, Cai W, Zheng Y, Evers BM, She QB. ERK And Akt signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer. Oncogene. 2014;33:1828–39.CrossRefPubMedGoogle Scholar
Yao YL, Shao J, Zhang C, Wu JH, Zhang QH, Wang JJ, et al. Proliferation of colorectal cancer is promoted by two signaling transduction expression patterns: ErbB2/erbB3/Akt and met/ErbB3/MAPK. PLoS One. 2013;8:e78086.CrossRefPubMedPubMedCentralGoogle Scholar
Yen L, Cao Z, Wu X, Ingalla ER, Baron C, Young LJ, et al. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth. Cancer Res. 2006;66:11279–86.CrossRefPubMedGoogle Scholar
von Kleist S, Chany E, Burtin P, King M, Fogh J. Immunohistology of the antigenic pattern of a continuous cell line from a human colon tumor. J Natl Cancer Inst. 1975;55:555–60.CrossRefGoogle Scholar
Xiao X, Gaffar I, Guo P, Wiersch J, Fischbach S, Peirish L, et al. M2 macrophages promote beta-cell proliferation by up-regulation of smad7. Proc Natl Acad Sci U S A. 2014;111:E1211–20.CrossRefPubMedPubMedCentralGoogle Scholar